Pharmacokinetic study of Piperine in Wistar rats after oral and intravenous administration

Promod Kumar Sahu, Anjna Sharma, Sheikh Rayees, Gurleen Kour, Amarinder Singh, Mowkshi Khullar, Asmita Magotra, Shravan Kumar Paswan, Mehak Gupta, Ishtiyaq Ahmad, Sumit Roy, Manoj Kumar Tikoo, Subhash Chander Sharma, Surjeet Singh, Gurdarshan Singh


To evaluate the potential of piperine as a therapeutic agent, we considered whole animal studies to characterize its pharmacokinetics (PK) in Wistar rats after oral and intravenous (i.v.) administration, using high performance liquid chromatography (HPLC). This study will enable in determination of piperine exposures needed to predict the dose regimen for clinical trials to test the proposed mechanism of action in enhancing the therapeutic efficacy of the concurrently administered drugs.

A single dose of piperine was administered intravenously (10 mg/kg) by jugular vein cannulation and orally (20 mg/kg) by oral gavage in male Wistar rats. Serial blood samples were collected and plasma piperine concentrations were determined using HPLC.

After intravenous administration the apparent terminal half-life (7.999 hr), apparent steady state volume of distribution (7.046 L/kg) and total body clearance (0.642 L/kg/hr) were calculated. After oral administration the apparent terminal half-life (1.224 hr), apparent steady state volume of distribution (4.692 L/kg) and total body clearance (2.656 L/kg/hr) were calculated. The peak plasma concentration of piperine in plasma after oral administration was found to be 0.983 μg/ml, occurred approximately 2 hr post-dose. The AUC(0-∞) of Piperine after oral and intravenous administration in rats were found out to be 7.53 μg*hr/ml and 15.6 μg*hr/ml, respectively. The absolute oral bioavailability of piperine was found to be 24%.

From the results of the experiment, it can be concluded that piperine achieves extensive distribution because of its large volume of distribution in the body. These studies are useful in interpreting preclinical efficacy studies of Piperine & predicting human pharmacokinetic through scaling technique.


Piperine; Pharmacokinetics; AUC; Bioavailability; HPLC; PDA detector

Full Text:



. Khanuja SPS, Arya JS, Santha Kumar TR, Saikia D, Kaur H, Singh M, Gupta SC, Shasany AK, Darokar MP, Srivastava SK, Gupta MM, Verma SC, Pal A. Nitrile glycoside useful as a bioenhancer of drugs and nutrients, process of its isolation from Moringa oleifera. United States Patent No.6,858,588; 2005.

. Kokate CK, Purohit AP, Khandelwal KR. Pharmacognosy, 29th ed. New Delhi, India: Nirali Prakashan.; 2002. p. 550-9.

. Badmaev V, Majeed M, Prakash L. Piperine derived from black pepper increases the plasma levels of coenzyme Q10 following oral supplementation. J Nutr Biochem. 2000; 11: 109-13.

. Mittal R, Gupta RL. In vitro antioxidant activity of piperine. Methods and Findings in Experimental and Clinical Pharmacology. 2000; 22(5):271–4.

. Vijayakumar RS, Surya D, Nalini N. Antioxidant efficacy of black pepper (Piper nigrum L.) and piperine in rats with high fat diet induced oxidative stress. Redox Report. 2004; 9(2):105–10.

. Park BS, Son DJ, Park YH, Kim TW, Lee SE. Antiplatelet effects of acidamides isolated from the fruits of Piper longum L. Phytomedicine. 2007; 14(12):853–5.

. Mujumdar AM, Dhuley JN, Deshmukh VK, Raman PH, Naik SR. Anti-inflammatory activity of piperine. Japanese Journal of Medical Science and Biology. 1990; 43(3):95–100.

. Kumar S, Singhal V, Roshan R, Sharma A, Rembhotkar GW, Ghosh B. Piperine inhibits TNF-α induced adhesion of neutrophils to endothelial monolayer through suppression of NF-κB and IκB kinase activation. European Journal of Pharmacology. 2007; 575(1–3):177–86.

. Taqvi SIH, Shah AJ, Gilani AH. Blood pressure lowering and vasomodulator effects of piperine. Journal of Cardiovascular Pharmacology. 2008; 52(5):452–8.

. Matsuda H, Ninomiya K, Morikawa T, Yasuda D, Yamaguchi I, Yoshikawa M. Protective effects of amide constituents from the fruit of Piper chaba on d-galactosamine/TNF-α-induced cell death in mouse hepatocytes. Bioorganic and Medicinal Chemistry Letters. 2008; 18(6):2038– 42.

. Panda S, Kar A. Piperine lowers the serum concentrations of thyroid hormones, glucose and hepatic 5_D activity in adult male mice. Hormone and Metabolic Research. 2003; 35(9):523–6.

. Bajad S, Bedi KL, Singla AK, Johri RK. Antidiarrhoeal activity of piperine in mice. Planta Medica. 2001; 67(3): 284–7.

. Kim SH, Lee YC. Piperine inhibits eosinophil infiltration and airway hyperresponsiveness by suppressing T cell activity and Th2 cytokine production in the ovalbumininduced asthma model. Journal of Pharmacy and Pharmacology. 2009; 61(3):353–9.

. Piyachaturawa P, Pholpramool C. Enhancement of fertilization by piperine in hamsters. Cell Biology International. 1997; 21(7):405–9.

. Atal CK, Dubey RK, Singh J. Biochemical basis of enhanced drug bioavailability by piperine: evidence that piperine is a potent inhibitor of drug metabolism. Journal of Pharmacology and Experimental Therapeutics. 1985; 232(1):258–62.

. Hiwale AR, Dhuley JN, Naik SR. Effect of co-administration of piperine on pharmacokinetics of beta-lactam antibiotics in rats. Indian Journal of Experimental Biology. 2002; 40: 277–81.

. Khajuria A, Zutshi U, Bedi KL. Permeability characteristics of piperine on oral absorption—an active alkaloid from peppers and a bioavailability enhancer. Indian Journal of Experimental Biology. 1998; 36: 46–50.

. Lambert JD, Hong J, Kim DH, Mishin VM, Yang CS. Piperine enhances the bioavailability of the tea polyphenol (-)-epigallocatechin-3- gallate in mice. Journal of Nutrition Research. 2004; 134:1948–52.

. Singh M, Varshneya C, Telang RS and Srivastava AK. Alteration of pharmacokinetics of oxytetracycline following oral administration of piper longum in hens. Journal of Veterinary Science. 2005; 6: 197–200.

. Bae, SK, JY Kim, SH Yang, JW Kim, T Kim and MG Lee. Pharmacokinetics of oltipraz in rat models of diabetes mellitus induced by alloxan or streptozotocin. Life Sci. 2006; 78(20): 2287-94.

. Lee DY, Lee MG, Shin HS, Lee I. Changes in omeprazol pharmacokinetics in rats with diabetes induced by alloxan or streptozotocin: faster clearance of omeprazol due to induction of hepatic CYP1A2 and 3A1. J Pharm Pharmaceut Sci. 2007; 10(4):420-33.

. Bajad S, Singla AK, Bedi KL. Liquid chromatographic method for determination of piperine in rat plasma: Application to pharmacokinetics. J Chromatogr. 2002; 776:245-49.

. Lei F, Xing DM, Xiang L, Zhao YN, Wang W, Zhang LJ, Du LJ. Pharmacokinetic study of ellagic acid in rat after oral administration of pomegranate leaf extract. Journal of Chromatography B. 2003; 796: 189-94.

. Ping TY, Qiao W, Wei Y, Zhi KD, Tong ZL. Determination of Shionone in Rat Plasma by HPLC and Its Pharmacokinetic study. Chinese Herbal Medicines. 2010; 2(1):132-5.

. Li L, Jiang XH, Yuan Y, Wang L, Yang JY, Zhou J. Pharmacokinetics of alcohol extract of Radix Salviae Miltiorrhiaze in rat in vivo. Chin Tradit Herb Drugs. 2005;36:1480-2.

. Hussain K, Ismail Z, Sadikun A, Ibrahim P. Bioactive Markers Based Pharmacokinetic Evaluation of Extracts of a Traditional Medicinal Plant, Piper sarmentosum. Evidence-Based Complementary and Alternative Medicine. 2011; 1:1-7.

. Singh SS. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. Current Drug Metabolism. 2006; 7(2):165-82.

. Mehta HR, Patel PB, Galani VJ. Factors affecting pharmacokinetics dispositions of drugs. IRJP. 2011; 2(5): 106-114.


  • There are currently no refbacks.

Copyright (c)

               AR Journals

18K, Street 1st, Gaytri Vihar, Pinto Park, Gwalior, M.P. India (Design) 2009-2021


Follow @arjournals on Twitter